Multiple sclerosis

EQS-News: Immunic to Participate in Investor and Scientific Conferences in May

Retrieved on: 
金曜日, 5月 10, 2024
Assistant professor, AFL, Research, Cleveland Clinic, Serum, Coeliac disease, Psychiatry, Multiple sclerosis, Communication, DDW, SIRT6, Annual general meeting, CMSC, Biotechnology, Pharmaceutical industry

NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

Key Points: 
  • NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
    May 12-14 and 21-22: Bio€quity Europe 2024.
  • Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in San Sebastián, Spain and virtually.
  • To schedule a meeting, please use the Bio€quity conference portal or contact Jessica Breu at: [email protected] .
  • Presentation Title: Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

Retrieved on: 
木曜日, 5月 9, 2024
Type 1 diabetes, Lupus, Jefferies Group, Acquisition, Sclerosis, Multiple sclerosis, BLA, Immune system, Music

ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.

Key Points: 
  • ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.
  • Frexalimab is in three Phase 3 clinical studies for the treatment of multiple sclerosis (MS).
  • Sanofi stated that potential non-risk-adjusted peak sales for frexalimab may be greater than €5 billion (December 7, 2023 R&D Day).
  • Royalty Pharma estimates frexalimab, if approved, will generate royalties through 2041.

FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome

Retrieved on: 
水曜日, 5月 8, 2024
FDA, Speech, Hope, Angelman syndrome, Food, Neuroinflammation, Parkinson's disease, Neurodevelopmental disorder, Epilepsy, Research, Spectrum, Seizure, Alzheimer's disease, Disease, Therapy, Patient, DSM-IV codes, Intellectual disability, Multiple sclerosis, Pharmaceutical industry

Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of Angelman syndrome (AS).

Key Points: 
  • Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of Angelman syndrome (AS).
  • Angelman Syndrome (AS) is a rare neurodevelopmental disorder characterized by developmental delay, intellectual disability, speech impairment, and motor abnormalities.
  • Currently, there is no specific treatment approved for preventing or controlling AS.
  • “Procuring orphan designation for Bi104 is a major milestone for us and validates our technology and formulation to initiate a clinical program.

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
Genetics, Multiple myeloma, MRD, ODAC, Patient, ADPT, Adaptation, Multiple sclerosis, Interest, Video game

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024.
  • The MRD business, which contributed 78% of revenue, grew 52% versus the first quarter of 2023.
    clonoSEQ test volume in the first quarter of 2024 grew 41% to 17,040 tests delivered versus the first quarter of 2023.
  • Revenue was $41.9 million for the quarter ended March 31, 2024, representing an 11% increase from the first quarter in the prior year.
  • Adaptive Biotechnologies will host a conference call to discuss its first quarter 2024 financial results after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time.

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Retrieved on: 
火曜日, 5月 7, 2024
Inflammation, NEA, Science, CD19, Patient, Pivotal, Coombs test, B cell, Wellington Management Company, Health, Norwest Venture Partners, I&I, Sclerosis, Multiple sclerosis, Pharmaceutical industry

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, today announced the closing of an upsized $200 million Series C preferred stock financing. The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Additional new investors, the Federated Hermes Kaufmann Funds, and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital participated in the financing. In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.

Key Points: 
  • The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital.
  • In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.
  • “Their commitment to Zenas is a testament to our vision to be a global leader in bringing innovative immunology-based therapies to patients around the world.
  • “At SR One, we invest in companies like Zenas whose science has the potential to rewrite the medical textbooks and meaningfully transform patient care.

INCREDIBLE SHRINKING BRAIN Shows the Physical Realities Behind Depression, Bipolar Disorder and Schizophrenia.

Retrieved on: 
火曜日, 5月 7, 2024
Learning, Bipolar disorder, Neuroscience, Death, Neurology, Depression, DSM-IV codes, Brain damage, Multiple sclerosis, Memory, Neuron, Pharmacology

Charleston, SC, May 07, 2024 (GLOBE NEWSWIRE) -- Neuroscience has discovered a toxic brain process termed hyperapoptosis.

Key Points: 
  • Charleston, SC, May 07, 2024 (GLOBE NEWSWIRE) -- Neuroscience has discovered a toxic brain process termed hyperapoptosis.
  • It is strictly a physical phenomenon causing accelerated death to neurons and shrinking of brain parts, visible on brain scans i.e., of the hippocampi, responsible for memory and learning.
  • Most neurologists, being aware neurological diseases like multiple sclerosis and Alzheimer’s disease are subjected to it, attempt to delay/inhibit the correlated brain damage with their sophisticated pharmacological skills.
  • The result is people with the aforementioned so-called “mental” diseases live 15 years less, suffer more and can have years of incapacitation.

CIONIC Unveils New Offerings to Address Full Spectrum of Mobility Challenges with New Activities of Daily Living Exercise Regimen and Training Reports for Patients with Disabilities

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Health Technology, Retail, Data Management, Technology, Apps, Applications, General Health, Women, Medical Devices, Discount, Variety, Men, Family, Software, Consumer, Health, Mobile, Wireless, Leg, Hope, Safety, Disability, Bionics, Smartphone, Stroke, Wearable, Therapy, Patient, Movement, Thomas Edison, Gold, Nervous system, Multiple sclerosis, Multimedia, Marketing, Tetraplegia, Walking

The durable leg sleeve is transforming how device-based therapeutics are assisting patients with multiple sclerosis, strokes, spinal cord injuries, and other upper motor neuron diagnoses.

Key Points: 
  • The durable leg sleeve is transforming how device-based therapeutics are assisting patients with multiple sclerosis, strokes, spinal cord injuries, and other upper motor neuron diagnoses.
  • View the full release here: https://www.businesswire.com/news/home/20240509998099/en/
    The FDA-Cleared Cionic Neural Sleeve (Photo: Business Wire)
    “At CIONIC, we are obsessed with improving function for the millions living with impaired mobility.
  • We continually evaluate our offering and incorporate customer feedback to introduce meaningful changes through software updates,” said Jeremiah Robison, CIONIC Founder and CEO.
  • "By providing a wider variety of functional movement training and detailed progress reports, we're empowering our users with more tools to increase their functional mobility and independence."

Autoimmune Disease Diagnostics Market Research, Size, Global Forecasts 2024-2030: Robotics and AI, Autoantibody Assays and Genetic Testing, & Innovative Biomarkers Drive Expansion - ResearchAndMarkets.com

Retrieved on: 
木曜日, 5月 9, 2024
Robotics, Medical Devices, Health, Technology, Health Technology, Artificial Intelligence, Mortality, Diagnosis, AI, Prognosis, Research, Heart, Diabetes, Insurance, SADS, Genetic testing, Point-of-care testing, Automation, Autoimmune disease, Arthritis, Patient, Inflammatory bowel disease, Rheumatoid arthritis, Physician, Consciousness, Arthritis Foundation, Lupus, Biomarker, Wipro, Multiple sclerosis, Disease, Vaccine

The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.

Key Points: 
  • The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.
  • By product, the global autoimmune diseases diagnostics market is fragmented into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs.
  • The global autoimmune diseases diagnostics market is segmented into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics.
  • By indication, the global autoimmune diseases diagnostics market is categorized into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others.

PLK Targeted Therapies Market & Clinical Trials 2024: Onvansertib Leading the Way in PLK1 Inhibition, Pioneering Breakthroughs in Small Cell Lung Cancer and Chronic Myelomonocytic Leukemia Treatment - ResearchAndMarkets.com

Retrieved on: 
火曜日, 5月 7, 2024
Health, Clinical Trials, Cytokinesis, Immunotherapy, Cancer, Chronic myelomonocytic leukemia, Inflammation, Disorder, Safety, Breast cancer, Viral, Apoptosis, SCLC, Cell proliferation, Research, Cell cycle, Carcinoma, DNA, Mitosis, Indication, Patient, Rheumatoid arthritis, Hepatitis B virus, Virus, Proteolysis targeting chimera, Multiple sclerosis, HIV, Messenger, PLK, Lupus, Genome, Biomarker, Medicine, PLK1, DA, HBV, Pharmaceutical industry

The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials.
  • The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
  • In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas.